Imunon, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Imunon, Inc. is a clinical-stage biotechnology company specializing in immunotherapies and vaccine development. The company’s core products include IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy designed for the localized treatment of advanced ovarian cancer; the PlaCCine® DNA vaccine platform, which offers enhanced durability and temperature stability compared to mRNA vaccines; and IMNN-101, a COVID-19 booster vaccine candidate. Imunon develops these products using its proprietary TheraPlas nanoparticle delivery platform, focusing on oncology and infectious disease markets. Imunon operates primarily in the United States, conducting clinical trials and research to advance its pipeline therapies. Founded in 1982 and headquartered in Waltham, Massachusetts, the company targets patients with advanced cancers and infectious diseases requiring innovative immunotherapy solutions. Imunon leverages collaborations and partnerships to accelerate the development and commercialization of its technologies. In recent developments, Imunon has initiated and expanded Phase 3 clinical trials for IMNN-001, demonstrating significant overall survival benefits in ovarian cancer patients, with enrollment expansions ongoing. The company also presented positive data on its PlaCCine vaccine technology at key international vaccine conferences in late 2025 and is actively seeking strategic partnerships to advance this platform. IMNN-101 clinical results further bolster the company’s vaccine portfolio. Imunon’s recent financial reports highlight robust clinical progress, with planned registrational studies and adaptive trial designs aligned with FDA guidance to support upcoming approvals and commercialization.
Celsion Corporation Announces Company Name Change to Imunon, Inc.
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Why Celsion Shares Are Pulling Back Today